22 May 2013
Keywords: expanded, use, novartis, sandostatin, lar, uk, swiss
Article | 05 July 2004
Swiss drug major Novartis' Sandostatin LAR (octreotide acetate forinjectable suspension) is now approved in the UK for patients with
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 July 2004
21 May 2013
© 2013 thepharmaletter.com